<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357522</url>
  </required_header>
  <id_info>
    <org_study_id>201904002</org_study_id>
    <nct_id>NCT04357522</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers</brief_title>
  <official_title>A Single-center, Randomised, Blind, Similar Vaccine Control, Non-inferior Designed Phase III Clinical Trial to Evaluate Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal
      Conjugate Vaccine in healthy volunteers aged 2 and 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity study endpoint</measure>
    <time_frame>30 day after each vaccination</time_frame>
    <description>Percentage of participants with seroresponse to each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety study endpoint</measure>
    <time_frame>30 day after each vaccination</time_frame>
    <description>Occurrence of adverse events during a 30 day follow-up period after each vaccination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1950</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>15-Valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-Valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.</description>
    <arm_group_label>Positive control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged above 2 months (minimum to 6 weeks), term (37-42 weeks gestation) and birth
             weight â‰¥2.5 kg.

          -  The guardian understands the vaccination and research procedures, volunteers to
             participate in the research and sign the informed consent.

          -  The guardian can follow the clinical research program, will be able to follow up until
             3 years after booster immunization and have the ability to use thermometers, scale and
             fill in diary and contact cards as required.

          -  There was no history of other live vaccines in the past 14 days and no history of
             other inactivated vaccines in the seventh day.

          -  Subaxillary body temperature &lt;=37.0 C.

          -  Determine health based on medical history, physical examination, and researcher's
             judgment.

        Exclusion Criteria:

          -  Have been vaccinated a listed or experimental pneumococcal vaccine.

          -  History of invasive diseases caused by Streptococcus pneumoniae confirmed by bacterial
             culture in the past.

          -  In the past, there was any history of vaccination or serious allergy to drugs. In the
             past, fever of over 39.5 C related to vaccination occurred in biological products for
             vaccination and prophylaxis.

          -  History of convulsion, epilepsy, encephalopathy and psychiatry or family history.

          -  Had abnormal labor (dystocia, device midwifery), history of asphyxia rescue and nerve
             organ damage.

          -  History of pathological jaundice confirmed by diagnosis.

          -  A history of thrombocytopenia or other coagulation disorders with definite diagnosis.

          -  Human serum gamma globulin injection after birth.

          -  There are known or suspected immunological abnormalities, including immunosuppressive
             therapy (radiotherapy, chemotherapy, corticosteroids, antimetabolites, cytotoxic
             drugs), HIV infection, etc.

          -  Congenital malformations, severe malnutrition, developmental disorders, genetic
             defects (e.g. broad bean disease).

          -  Severe chronic disease, infectious disease, active infection, liver disease, kidney
             disease, cardiovascular disease, malignant tumor.

          -  Severe asthma.

          -  Systemic rash, dermatophytes, skin pus or blister.

          -  Participation in other drug clinical trials.

          -  Anything that the researcher considers likely to affect the evaluation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Du Lin, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daming Center for Disease Control and Prevention</name>
      <address>
        <city>Daming</city>
        <state>Hebei</state>
        <zip>056900</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liu Yong</last_name>
      <phone>86 13831030598</phone>
      <email>dmxcdc@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laishui Center for Disease Control and Prevention</name>
      <address>
        <city>Laishui</city>
        <state>Hebei</state>
        <zip>074199</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhang Po</last_name>
      <phone>86 18903365570</phone>
      <email>m18903365570@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhengding Center for Disease Control and Prevention</name>
      <address>
        <city>Zhengding</city>
        <state>Hebei</state>
        <zip>050800</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhang Xinjiang</last_name>
      <phone>86 13933170448</phone>
      <email>13473793896@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

